{"id":2271,"date":"2025-12-30T17:33:20","date_gmt":"2025-12-30T17:33:20","guid":{"rendered":"https:\/\/journal.nncf.kz\/?p=2271"},"modified":"2026-03-11T17:51:41","modified_gmt":"2026-03-11T17:51:41","slug":"%d1%84%d0%b0%d1%80%d0%bc%d0%b0%d0%ba%d0%be%d1%8d%d0%ba%d0%be%d0%bd%d0%be%d0%bc%d0%b8%d1%87%d0%b5%d1%81%d0%ba%d0%b0%d1%8f-%d0%be%d1%86%d0%b5%d0%bd%d0%ba%d0%b0-%d0%b1%d0%b0%d0%b7%d0%b8%d1%81%d0%bd%d0%be","status":"publish","type":"post","link":"https:\/\/journal.nncf.kz\/en\/%d1%84%d0%b0%d1%80%d0%bc%d0%b0%d0%ba%d0%be%d1%8d%d0%ba%d0%be%d0%bd%d0%be%d0%bc%d0%b8%d1%87%d0%b5%d1%81%d0%ba%d0%b0%d1%8f-%d0%be%d1%86%d0%b5%d0%bd%d0%ba%d0%b0-%d0%b1%d0%b0%d0%b7%d0%b8%d1%81%d0%bd%d0%be\/","title":{"rendered":"PHARMACOECONOMIC COST-EFFECTIVENESS ANALYSIS OF BASIC ASTHMA THERAPY REGIMENS IN CHILDREN IN KAZAKHSTAN"},"content":{"rendered":"

Received: 19.10.2025
\nAccepted: 05.12.2025
\nPublished online: 31.12.2025
\nUDC: 616.248-053.2:615.1
\nDOI: 10.26212\/2227-1937.2025.49.84.004<\/a><\/p>\n

 <\/p>\n

PHARMACOECONOMIC COST-EFFECTIVENESS ANALYSIS OF BASIC ASTHMA THERAPY<\/strong>
\nREGIMENS IN CHILDREN IN KAZAKHSTAN<\/strong><\/p>\n

 <\/p>\n

Serikbayeva E.A.\u00b9, Zhakipbekov K.S.\u00b9, SHimirova ZH.K. \u00b2, Umurzakhova G.Zh.\u00b2<\/p>\n

\u00b9 NJSC \u00abAsfendiyarov Kazakh National Medical University\u00bb,
\nKazakhstan, Almaty<\/p>\n

\u00b2 \u00abSouth Kazakhstan Medical Academy\u00bb, Kazakhstan, Shymkent<\/p>\n

 <\/p>\n

Introduction<\/strong>: Bronchial asthma is a chronic lung disease characterized by inflammation of the
\nbronchial tree and spasm of the smooth muscles of the airways, leading to breathing difficulties.
\nBronchial asthma can affect individuals of any gender and age. Its symptoms include cough,
\npredominantly at night, distant wheezing during exhalation, and in more severe cases – chest
\ntightness, difficulty with deep breathing, and shortness of breath during physical activity or even
\nat rest.<\/p>\n

Research Objective<\/strong>: to calculate the pharmacoeconomic indicator, namely the costeffectiveness ratio (CER), for the treatment of children with bronchial asthma using combined
\nregimens of bronchodilators and inhaled corticosteroids.<\/p>\n

Materials and Methods<\/strong>. The study involved 54 children aged 6 to 12 years, who were divided
\ninto 6 groups according to age and the severity of bronchial asthma. Treatment effectiveness
\nwas assessed by calculating the percentage difference between the frequency of exacerbations
\nand the number of patients. Pharmacoeconomic data were calculated using the costeffectiveness ratio (CER).<\/p>\n

Results<\/strong>: The study revealed that over the years, the proportion of patients receiving Symbicort
\nTurbuhaler increased to 5.5% in mild, 7.7% in moderate, and 9.7% in severe cases, accompanied
\nby an increase in the pharmacoeconomic index to 1300 USD. The use of Symbicort Turbuhaler at
\nall stages of bronchial asthma helps to reduce the frequency of exacerbations and relieve the
\nfinancial burden on the state budget and the healthcare system. This study is similar to the
\nreferenced research, as it also involves the use of the combined drug Symbicort Turbuhaler
\n(budesonide\/formoterol), which positively affects both clinical effectiveness and economic
\noutcomes.<\/p>\n

Discussion<\/strong>: This study aimed to determine the most effective and least costly treatment
\nregimen for children with bronchial asthma using the CER coefficient. However, the obtained
\nresults have some limitations, such as a relatively small sample size and the use of only three
\ntreatment regimens in two age groups with varying severity. The findings indicate that the most
\neffective and beneficial treatment was observed in children aged 6 – 8 years with mild asthma.
\nAs the dosage was calculated based on age, the cost of treatment in the 6 – 8 age group was lower
\nfor any severity compared to the 9\u201312 age group. Additionally, the coefficient was calculated
\nconsidering the annual frequency of exacerbations, and its values did not vary significantly,
\nranging from 40\u201370%, which also influenced the results.<\/p>\n

Keywords<\/strong>: asthma exacerbation, economic evaluation of asthma treatment, pharmacotherapy,
\ndrug safety, accessibility of therapy for children with asthma.<\/p>\n

 <\/p>\n

\r\n\t\"\"\r\n\r\n\t
\r\n\t\t\u0421\u043a\u0430\u0447\u0430\u0442\u044c: PHARMACOECONOMIC COST-EFFECTIVENESS ANALYSIS OF BASIC ASTHMA THERAPY REGIMENS IN CHILDREN IN KAZAKHSTAN<\/a>\r\n\t\t
<\/div>\r\n\t\t
\u0421\u043a\u0430\u0447\u0430\u043d\u043e: 56, \u0440\u0430\u0437\u043c\u0435\u0440: 0<\/div>\r\n\t<\/div>\r\n\t\r\n<\/div>\r\n\r\n